Application/NN
of/IN
Whole/JJ
Exome/NN
Sequencing/NN
to/TO
Identify/VB
Disease-Causing/NN
Variants/NNS
in/IN
Inherited/JJ
Human/JJ
Diseases/NNS
./.
====================
The/DT
recent/JJ
advent/JJ
of/IN
next-generation/NN
sequencing/NN
technologies/NNS
has/VBZ
dramatically/RB
changed/VBD
the/DT
nature/NN
of/IN
biomedical/JJ
research/NN
./.
====================
Human/JJ
genetics/NNS
is/VBZ
no/DT
exception-it/NN
has/VBZ
never/RB
been/VBN
easier/RBR
to/TO
interrogate/VB
human/JJ
patient/NN
genomes/NNS
at/IN
the/DT
nucleotide/NN
level/NN
to/TO
identify/VB
disease-associated/JJ
variants/NNS
./.
====================
To/TO
further/RBR
facilitate/VBP
the/DT
efficiency/NN
of/IN
this/DT
approach/NN
,/,
whole/JJ
exome/NN
sequencing/NN
(/(
WES/NNS
)/)
was/VBD
first/JJ
developed/VBD
in/IN
2009/CD
./.
====================
Over/RB
the/DT
past/NN
three/CD
years/NNS
,/,
multiple/JJ
groups/NNS
have/VBP
demonstrated/VBN
the/DT
power/JJ
of/IN
WES/NN
through/IN
robust/JJ
disease-associated/JJ
variant/JJ
discoveries/NNS
across/IN
a/DT
diverse/JJ
spectrum/NN
of/IN
human/JJ
diseases/NNS
./.
====================
Here/RB
,/,
we/PRP
review/VBP
the/DT
application/NN
of/IN
WES/NN
to/TO
different/JJ
types/NNS
of/IN
inherited/VBN
human/JJ
diseases/NNS
and/CC
discuss/VBP
analytical/JJ
challenges/NNS
and/CC
possible/JJ
solutions/NNS
,/,
with/IN
the/DT
aim/NN
of/IN
providing/VBG
a/DT
practical/JJ
guide/NN
for/IN
the/DT
effective/JJ
use/NN
of/IN
this/DT
technology/NN
./.
====================
Whole/IN
exome/JJ
sequencing/NN
(/(
WES/NNS
)/)
is/VBZ
a/DT
technique/NN
to/TO
selectively/RB
capture/NN
and/CC
sequence/NN
the/DT
coding/VBG
regions/NNS
of/IN
all/DT
annotated/JJ
protein-coding/VBG
genes/NNS
./.
====================
Coupled/JJ
with/IN
next-generation/NN
sequencing/NN
(/(
NGS/NN
)/)
platforms/VBZ
,/,
it/PRP
enables/VBZ
the/DT
analysis/NN
of/IN
functional/JJ
regions/NNS
of/IN
the/DT
human/JJ
genome/NN
with/IN
unprecedented/JJ
efficiency/NN
./.
====================
Since/IN
its/PRP$
first/JJ
reported/VBD
application/NN
[/(
1/CD
,/,
2/CD
]/)
,/,
WES/NN
has/VBZ
emerged/VBN
as/IN
a/DT
powerful/JJ
and/CC
popular/JJ
tool/NN
for/IN
researchers/NNS
elucidating/VBG
genetic/JJ
variants/NNS
underlying/VBG
human/JJ
diseases/NNS
(/(
Fig/NN
./.
====================
1/CD
)/)
despite/IN
certain/JJ
limitations/NNS
(/(
see/VB
below/IN
)/)
./.
====================
WES/NNS
pipelines/NNS
generally/RB
follow/VBP
a/DT
similar/JJ
process/NN
,/,
regardless/RB
of/IN
the/DT
capture/NN
method/NN
and/CC
NGS/NN
platform/NN
used/VBN
,/,
as/IN
summarized/VBN
in/IN
Fig/NN
./.
====================
2/CD
./.
====================
The/DT
experimental/JJ
pipeline/NN
can/MD
be/VB
divided/VBN
into/IN
two/CD
parts/NNS
:/:
1/CD
)/)
preparing/VBG
genomic/JJ
DNA/NN
libraries/NNS
and/CC
hybridizing/VBG
them/PRP
to/TO
capture/NN
arrays/NNS
and/CC
2/CD
)/)
NGS/NN
of/IN
the/DT
eluted/VBN
target/NN
fragments/NNS
./.
====================
There/EX
are/VBP
a/DT
number/NN
of/IN
commercially/RB
available/JJ
capture/NN
arrays/NNS
,/,
and/CC
their/PRP$
strengths/NNS
and/CC
weaknesses/NNS
have/VBP
been/VBN
well/RB
described/VBN
elsewhere/RB
[/(
3/CD
]/)
./.
====================
Once/RB
short/JJ
sequencing/NN
reads/VBZ
have/VBP
been/VBN
generated/VBN
,/,
they/PRP
are/VBP
mapped/VBN
to/TO
the/DT
reference/NN
human/JJ
genome/NN
,/,
and/CC
variant/JJ
calling/JJ
is/VBZ
carried/VBN
out/RP
./.
====================
Subsequent/JJ
annotation/NN
of/IN
these/DT
variants/NNS
is/VBZ
necessary/JJ
to/TO
further/RBR
evaluate/VB
their/PRP$
potential/JJ
biological/JJ
effect/NN
;/:
publicly/RB
available/JJ
software/RB
and/CC
databases/NNS
can/MD
be/VB
used/VBN
for/IN
this/DT
purpose/NN
./.
====================
WES/NNS
is/VBZ
a/DT
robust/JJ
technology/NN
that/WDT
is/VBZ
extremely/RB
practical/JJ
for/IN
investigating/VBG
coding/VBG
variation/NN
at/IN
the/DT
genome-wide/NN
level/NN
./.
====================
Despite/IN
the/DT
plummeting/JJ
cost/JJ
of/IN
sequencing/NN
in/IN
the/DT
past/NN
few/JJ
years/NNS
,/,
WES/NN
at/IN
mean/JJ
coverage/NN
depth/NN
of/IN
100×/CD
still/RB
costs/VBZ
five/CD
times/NNS
less/RBR
than/IN
whole/JJ
genome/NN
sequencing/NN
(/(
WGS/NN
)/)
at/IN
mean/JJ
coverage/NN
depth/NN
30×/CD
./.
====================
In/IN
addition/NN
,/,
the/DT
size/NN
of/IN
WES/NN
data/NNS
per/IN
patient/NN
is/VBZ
approximately/RB
a/DT
sixth/JJ
of/IN
WGS/NN
data/NNS
,/,
resulting/VBG
in/IN
reduced/VBN
processing/NN
time/NN
and/CC
imposing/VBG
less/RBR
of/IN
a/DT
burden/JJ
in/IN
terms/NNS
of/IN
data/NNS
storage/VBP
./.
====================
However/RB
,/,
it/PRP
is/VBZ
important/JJ
to/TO
understand/VB
the/DT
limitations/NNS
of/IN
WES/NN
technology/NN
./.
====================
Certain/JJ
protein-coding/VBG
regions/NNS
might/MD
not/RB
be/VB
covered/VBN
due/JJ
to/TO
incomplete/VB
annotation/NN
of/IN
the/DT
human/JJ
genome/NN
./.
====================
Further/RB
,/,
WES/NN
does/VBZ
not/RB
cover/RB
potentially/RB
functional/JJ
non-coding/JJ
elements/NNS
,/,
including/VBG
untranslated/JJ
regions/NNS
,/,
enhancers/NNS
,/,
and/CC
long-noncoding/JJ
RNAs/NNS
,/,
although/IN
these/DT
are/VBP
,/,
in/IN
themselves/DT
,/,
not/RB
clearly/RB
defined/VBN
./.
====================
Another/DT
drawback/VBP
to/TO
WES/NN
is/VBZ
the/DT
limited/JJ
ability/NN
to/TO
detect/VB
structural/JJ
variations/NNS
,/,
such/JJ
as/IN
copy-number/NN
variations/NNS
,/,
translocations/NNS
,/,
and/CC
inversions/NNS
./.
====================
In/IN
spite/NN
of/IN
these/DT
limitations/NNS
,/,
WES/NN
is/VBZ
still/RB
the/DT
tool/NN
of/IN
choice/NN
for/IN
many/JJ
researchers-its/NNS
practical/JJ
advantages/VBZ
allow/VBP
large/JJ
numbers/NNS
of/IN
patients/NNS
to/TO
be/VB
screened/VBN
in/IN
a/DT
robust/JJ
fashion/NN
,/,
a/DT
crucial/JJ
aspect/NN
of/IN
mutation/NN
discovery/RB
in/IN
human/JJ
genetics/NNS
research/NN
./.
====================
WES/NNS
has/VBZ
been/VBN
used/VBN
in/IN
identifying/VBG
genetic/JJ
variants/NNS
associated/VBN
with/IN
a/DT
variety/NN
of/IN
diseases/NNS
./.
====================
Here/RB
,/,
we/PRP
discuss/VBP
different/JJ
categories/NNS
of/IN
inherited/VBN
human/JJ
disease/NN
and/CC
the/DT
methodology/NN
employed/VBN
to/TO
examine/VB
each/DT
case/NN
./.
====================
Diseases/NNS
inherited/VBN
in/IN
a/DT
recessive/JJ
pattern/NN
have/VBP
traditionally/RB
been/VBN
highly/RB
amenable/JJ
to/TO
genetic/JJ
analysis/NN
,/,
due/JJ
to/TO
the/DT
fact/NN
that/IN
homozygous/JJ
variants/NNS
are/VBP
easily/RB
detectable/JJ
./.
====================
Previously/RB
,/,
if/IN
a/DT
large/JJ
family/NN
with/IN
many/JJ
affected/VBN
members/NNS
was/VBD
available/JJ
for/IN
pedigree/JJ
analysis/NN
,/,
one/CD
would/MD
perform/VB
linkage/NN
analysis/NN
by/IN
genotyping/VBG
family/NN
members/NNS
in/IN
order/NN
to/TO
identify/VB
relatively/RB
short/JJ
genomic/JJ
intervals/NNS
that/IN
presumably/RB
contained/VBD
the/DT
disease-associated/JJ
variant/JJ
./.
====================
Direct/JJ
interrogation/NN
of/IN
entire/JJ
genomes/NNS
for/IN
homozygous/JJ
variants/NNS
is/VBZ
now/RB
possible/JJ
with/IN
NGS/NN
technologies/NNS
,/,
and/CC
public/JJ
datasets/NNS
can/MD
be/VB
used/VBN
to/TO
exclude/VB
common/JJ
variants/NNS
that/IN
are/VBP
less/RBR
probable/JJ
to/TO
be/VB
disease-causing/VBG
./.
====================
Identifying/VBG
recessive/JJ
variants/NNS
is/VBZ
especially/RB
straightforward/JJ
if/IN
the/DT
proband/NN
is/VBZ
a/DT
product/NN
of/IN
a/DT
consanguineous/JJ
marriage-sequencing/VBG
the/DT
entire/JJ
exome/JJ
of/IN
the/DT
patient/NN
would/MD
likely/RB
yield/VB
a/DT
manageable/JJ
number/NN
of/IN
rare/JJ
homozygous/JJ
variants/NNS
,/,
and/CC
further/RB
studies/NNS
could/MD
be/VB
performed/VBN
to/TO
investigate/VB
the/DT
functional/JJ
relevance/NN
of/IN
these/DT
variants/NNS
./.
====================
In/IN
one/CD
of/IN
the/DT
earliest/JJS
reports/NNS
of/IN
the/DT
application/NN
of/IN
WES/NN
technology/NN
,/,
Bilgüvar/JJ
et/FW
al/JJ
./.
====================
[/(
4/CD
]/)
identified/VBD
recessive/JJ
mutations/NNS
in/IN
WDR62/NN
in/IN
multiple/JJ
Turkish/JJ
consanguineous/JJ
patients/NNS
with/IN
severe/JJ
developmental/JJ
brain/NN
defects/NNS
./.
====================
Very/RB
little/JJ
was/VBD
known/VBN
about/IN
WDR62/NN
at/IN
that/DT
time/NN
,/,
but/CC
subsequent/JJ
genetic/JJ
and/CC
functional/JJ
studies/NNS
have/VBP
since/IN
validated/VBN
the/DT
importance/NN
of/IN
this/DT
gene/NN
in/IN
proper/JJ
brain/NN
development/NN
./.
====================
More/RBR
recently/RB
,/,
a/DT
large/JJ
cohort/JJ
of/IN
patients/NNS
of/IN
similar/JJ
genetic/JJ
status/NN
and/CC
clinical/JJ
manifestation/NN
were/VBD
analyzed/VBN
using/VBG
homozygosity/NN
mapping/VBG
from/IN
WES/NN
data/NNS
[/(
5/CD
]/)
./.
====================
The/DT
authors/NNS
uncovered/JJ
22/CD
genes/NNS
not/RB
previously/RB
identified/VBN
as/IN
disease-causing/JJ
,/,
further/RB
demonstrating/VBG
the/DT
power/JJ
of/IN
WES/NN
as/IN
an/DT
ideal/JJ
tool/NN
for/IN
gene/NN
discovery/NN
./.
====================
Mendelian/JJ
diseases/NNS
with/IN
dominant/JJ
modes/NNS
of/IN
inheritance/NN
pose/VBP
greater/JJR
technical/JJ
challenges/NNS
for/IN
genetic/JJ
analysis/NN
./.
====================
Heterozygous/JJ
variants/NNS
are/VBP
generally/RB
more/RBR
difficult/JJ
to/TO
detect/VB
and/CC
analyze/VB
,/,
not/RB
only/RB
due/JJ
to/TO
their/PRP$
sheer/NN
number/NN
as/IN
compared/VBN
to/TO
homozygous/JJ
variants/NNS
but/CC
also/RB
because/IN
they/PRP
are/VBP
subjected/VBN
to/TO
higher/JJR
false/VBP
positive/JJ
and/CC
false/VBP
negative/JJ
errors/NNS
./.
====================
Nevertheless/RB
,/,
one/CD
could/MD
still/RB
design/NN
one/CD
of/IN
the/DT
following/VBG
experiments/NNS
to/TO
elucidate/VB
the/DT
genetic/JJ
architecture/NN
underlying/VBG
these/DT
diseases/NNS
,/,
depending/VBG
on/IN
the/DT
availability/NN
of/IN
patient/NN
cohorts/NNS
and/CC
the/DT
effect/NN
of/IN
the/DT
disease/NN
on/IN
reproductive/JJ
fitness/RB
./.
====================
Familial/JJ
cohort/NN
====================
If/IN
large/JJ
families/NNS
with/IN
the/DT
disease/NN
of/IN
interest/NN
are/VBP
available/JJ
,/,
WES/NN
should/MD
be/VB
performed/VBN
on/IN
at/IN
least/JJS
two/CD
affected/VBN
family/NN
members/NNS
./.
====================
In/IN
analyzing/VBG
the/DT
results/NNS
,/,
any/DT
shared/JJ
variants/NNS
could/MD
potentially/RB
be/VB
disease-causing/VBG
;/:
using/VBG
linkage/NN
data/NNS
to/TO
focus/VB
on/IN
the/DT
variants/NNS
located/JJ
in/IN
linked/VBN
intervals/NNS
would/MD
greatly/RB
reduce/VBP
the/DT
number/NN
of/IN
variants/NNS
to/TO
be/VB
considered/VBN
./.
====================
A/DT
recent/JJ
example/NN
of/IN
such/JJ
an/DT
approach/NN
is/VBZ
a/DT
WES/NN
study/NN
on/IN
familial/JJ
amyotrophic/JJ
lateral/JJ
sclerosis/NN
(/(
FALS/NNS
)/)
[/(
6/CD
]/)
./.
====================
The/DT
authors/NNS
recruited/VBD
two/CD
large/JJ
families/NNS
with/IN
FALS/NN
and/CC
selected/VBN
two/CD
affected/VBN
members/NNS
with/IN
the/DT
greatest/JJS
genetic/JJ
distance/NN
from/IN
each/DT
family/NN
for/IN
WES/NN
./.
====================
Among/IN
the/DT
rare/JJ
functional/JJ
variants/NNS
that/IN
were/VBD
identified/VBN
,/,
they/PRP
tested/VBD
the/DT
shared/JJ
variants/NNS
for/IN
Mendelian/JJ
segregation/NN
among/IN
affected/VBN
family/NN
members/NNS
,/,
eventually/RB
narrowing/VBG
their/PRP$
search/NN
down/RB
to/TO
a/DT
single/JJ
common/JJ
gene/NN
,/,
PFN1/NN
./.
====================
Non-familial/JJ
cohort/NN
====================
When/WRB
large/JJ
families/NNS
with/IN
the/DT
disease/NN
are/VBP
not/RB
readily/RB
available/JJ
,/,
one/CD
could/MD
perform/VB
WES/NN
on/IN
a/DT
number/NN
of/IN
unrelated/JJ
patients/NNS
with/IN
similar/JJ
clinical/JJ
manifestations/NNS
and/CC
select/JJ
genes/NNS
that/WDT
are/VBP
commonly/RB
mutated/VBN
in/IN
the/DT
patient/NN
cohort/VBP
./.
====================
In/IN
carrying/VBG
out/IN
such/JJ
an/DT
experiment/JJ
,/,
it/PRP
is/VBZ
important/JJ
to/TO
consider/VB
the/DT
background/NN
mutation/NN
burden/NN
of/IN
the/DT
entire/JJ
human/JJ
gene/NN
set/NN
;/:
it/PRP
is/VBZ
possible/JJ
that/IN
the/DT
longest/JJS
genes/NNS
might/MD
contain/VB
the/DT
highest/JJS
number/NN
of/IN
rare/JJ
functional/JJ
variants/NNS
and/CC
therefore/RB
appear/VBP
to/TO
be/VB
the/DT
most/JJS
interesting/JJ
./.
====================
To/TO
circumvent/VB
such/JJ
errors/NNS
in/IN
analysis/NN
,/,
the/DT
variant/JJ
burden/NN
of/IN
each/DT
gene/NN
should/MD
be/VB
normalized/VBN
using/VBG
data/NNS
from/IN
a/DT
control/JJ
population/NN
./.
====================
In/IN
a/DT
WES/NN
study/NN
of/IN
pseudohypoaldosteronism/NN
type/NN
II/CD
(/(
PHAII/NN
)/)
,/,
the/DT
variant/JJ
burden/NN
of/IN
every/DT
gene/NN
from/IN
11/CD
unrelated/JJ
patients/NNS
was/VBD
compared/VBN
against/IN
that/DT
of/IN
699/CD
controls/NNS
[/(
7/CD
]/)
./.
====================
A/DT
single/JJ
gene/NN
that/WDT
was/VBD
specifically/RB
enriched/VBN
for/IN
mutations/NNS
in/IN
the/DT
patient/NN
set/NN
,/,
KLHL3/NN
,/,
was/VBD
identified/VBN
(/(
5/CD
variants/NNS
from/IN
11/CD
patients/NNS
compared/VBD
to/TO
2/CD
from/IN
699/CD
controls/NNS
,/,
with/IN
p-value/JJ
of/IN
1.1/CD
×/CD
10-8/CD
)/)
./.
====================
Non-inheritable/JJ
diseases/NNS
====================
If/IN
the/DT
disease/NN
phenotype/NN
is/VBZ
severe/JJ
enough/IN
such/JJ
that/IN
it/PRP
affects/VBZ
reproductive/JJ
fitness/RB
,/,
one/CD
could/MD
hypothesize/VB
that/IN
de/FW
novo/FW
variants-variants/NNS
that/DT
emerged/VBN
during/IN
meiosis/NN
of/IN
the/DT
germ/NN
cells/NNS
that/WDT
are/VBP
unique/JJ
to/TO
the/DT
offspring-are/JJ
directly/RB
associated/VBN
with/IN
the/DT
disease/NN
./.
====================
These/DT
can/MD
be/VB
detected/VBN
by/IN
performing/VBG
trio-based/VBN
WES/NN
on/IN
the/DT
unaffected/JJ
parents/NNS
and/CC
the/DT
proband/NN
,/,
and/CC
variants/NNS
that/IN
are/VBP
present/JJ
in/IN
the/DT
offspring/VBG
only/RB
and/CC
not/RB
in/IN
the/DT
parents/NNS
will/MD
be/VB
called/VBN
de/FW
novo/FW
variants/NNS
./.
====================
The/DT
rate/NN
of/IN
de/FW
novo/FW
mutations/NNS
has/VBZ
been/VBN
shown/VBN
to/TO
be/VB
relatively/RB
stable/JJ
and/CC
affected/VBD
primarily/RB
by/IN
paternal/JJ
age/NN
[/(
8/CD
]/)
./.
====================
WES/NNS
of/IN
family/NN
quartets/NNS
can/MD
also/RB
be/VB
carried/VBN
out/RP
,/,
where/WRB
unaffected/JJ
siblings/NNS
are/VBP
recruited/VBN
simultaneously/RB
and/CC
their/PRP$
de/FW
novo/FW
mutations/NNS
are/VBP
compared/VBN
against/IN
those/DT
of/IN
the/DT
proband/NN
./.
====================
A/DT
series/NN
of/IN
studies/NNS
involving/VBG
autism/NN
trios/NNS
and/CC
quartets/NNS
recently/RB
demonstrated/VBD
that/IN
rare/JJ
de/FW
novo/FW
mutations/NNS
were/VBD
associated/VBN
with/IN
the/DT
risk/NN
of/IN
autism/NN
and/CC
identified/VBD
multiple/JJ
de/FW
novo/FW
mutations/NNS
in/IN
SCN2A/NN
,/,
KATNAL2/NN
,/,
and/CC
CHD8/NN
,/,
implicating/VBG
these/DT
genes/NNS
in/IN
the/DT
genetic/JJ
etiology/NN
underlying/VBG
autism/NN
[/(
9-11/CD
]/)
./.
====================
The/DT
majority/NN
of/IN
the/DT
disease/NN
burden/NN
that/IN
modern/NN
societies/NNS
endure/NN
can/MD
be/VB
attributed/VBN
to/TO
common/JJ
complex/NN
diseases/NNS
./.
====================
These/DT
diseases/NNS
typically/RB
have/VBP
both/CC
genetic/JJ
and/CC
environmental/JJ
causes/VBZ
,/,
and/CC
they/PRP
also/RB
possess/VBP
significant/JJ
genetic/JJ
heterogeneity/NN
,/,
making/VBG
the/DT
identification/NN
of/IN
disease-causing/VBG
genes/NNS
very/RB
challenging/JJ
./.
====================
Traditionally/RB
,/,
the/DT
use/NN
of/IN
linkage/NN
analysis/NN
of/IN
families/NNS
with/IN
extreme/JJ
disease/NN
phenotypes/NNS
has/VBZ
been/VBN
somewhat/RB
successful/JJ
in/IN
mutation/NN
discovery/NN
[/(
12/CD
]/)
./.
====================
However/RB
,/,
these/DT
mutations/NNS
are/VBP
particular/JJ
to/TO
patients/NNS
with/IN
extreme/JJ
phenotypes/NNS
and/CC
do/VBP
not/RB
explain/VB
the/DT
pathophysiology/NN
of/IN
disease/NN
for/IN
patients/NNS
in/IN
the/DT
general/JJ
population/NN
./.
====================
Large/JJ
genome-wide/NN
association/NN
studies/NNS
of/IN
common/JJ
variants/NNS
have/VBP
also/RB
been/VBN
employed/VBN
with/IN
limited/JJ
success/NN
;/:
the/DT
findings/NNS
in/IN
many/JJ
studies/NNS
are/VBP
not/RB
robust/JJ
and/CC
only/RB
explain/VBP
a/DT
small/JJ
fraction/NN
of/IN
the/DT
disease/NN
risk/NN
[/(
13/CD
]/)
./.
====================
As/IN
a/DT
result/NN
,/,
greater/JJR
attention/NN
has/VBZ
been/VBN
drawn/VBN
to/TO
profiling/VBG
rare/JJ
variants/NNS
with/IN
allele/NN
frequencies/NNS
of/IN
less/RBR
than/IN
1/CD
%/NN
in/IN
complex/NN
diseases/NNS
./.
====================
Taking/VBG
advantage/NN
of/IN
WES/NN
technology/NN
,/,
several/JJ
large-scale/JJ
projects/NNS
have/VBP
been/VBN
launched/VBN
./.
====================
One/CD
such/JJ
example/NN
is/VBZ
a/DT
project/JJ
led/VBD
by/IN
National/JJ
Heart/NN
,/,
Lung/NN
,/,
and/CC
Blood/NN
Institute/JJ
(/(
NHLBI/NN
)/)
to/TO
discover/JJ
novel/JJ
genes/NNS
underlying/VBG
cardiovascular/JJ
disorders/NNS
./.
====================
As/IN
a/DT
result/NN
of/IN
sequencing/NN
the/DT
exomes/NNS
of/IN
2,440/CD
individuals/NNS
,/,
the/DT
study/NN
reported/VBD
an/DT
excess/NN
of/IN
rare/JJ
functional/JJ
variants/NNS
and/CC
concluded/VBD
that/IN
large/JJ
numbers/NNS
of/IN
subjects/NNS
will/MD
be/VB
required/VBN
to/TO
attain/VB
sufficient/JJ
power/JJR
to/TO
discover/RB
variants/NNS
that/IN
are/VBP
significantly/RB
associated/VBN
with/IN
the/DT
disease/NN
traits/VBZ
[/(
14/CD
]/)
./.
====================
WES/NNS
yields/VBZ
extensive/JJ
lists/NNS
of/IN
genomic/JJ
variation/NN
,/,
and/CC
there/EX
are/VBP
many/JJ
important/JJ
caveats/NNS
to/TO
bear/VB
in/IN
mind/JJ
when/WRB
carrying/VBG
out/RP
analysis/NN
of/IN
such/JJ
data/NNS
./.
====================
In/IN
this/DT
section/NN
,/,
we/PRP
address/VBP
the/DT
potential/JJ
challenges/NNS
that/DT
the/DT
investigators/NNS
need/VBD
to/TO
consider/VB
when/WRB
designing/VBG
or/CC
performing/VBG
the/DT
experiments/NNS
./.
====================
Recent/JJ
improvements/NNS
of/IN
the/DT
WES/NN
technique/NN
in/IN
both/DT
experimental/JJ
and/CC
bioinformatics/NNS
pipelines/NNS
have/VBP
reduced/VBN
the/DT
occurrence/NN
of/IN
false/JJ
positive/JJ
(/(
false/RB
variant/JJ
that/DT
is/VBZ
called/VBN
true/JJ
)/)
and/CC
false/VBP
negative/JJ
(/(
true/JJ
variant/JJ
that/DT
is/VBZ
failed/VBN
to/TO
be/VB
called/VBN
)/)
variant/JJ
calls/NNS
substantially/RB
./.
====================
Currently/RB
,/,
we/PRP
can/MD
achieve/VB
~98/CD
%/NN
sensitivity/NN
and/CC
99.8/CD
%/NN
specificity/NN
from/IN
exome/DT
sequencing/NN
data/NNS
,/,
minimizing/VBG
the/DT
chance/NN
of/IN
missing/VBG
any/DT
true/JJ
variants/NNS
as/IN
compared/VBN
to/TO
the/DT
analysis/NN
of/IN
SNP/NN
array/NN
data/NNS
(/(
data/NNS
not/RB
shown/VBN
)/)
./.
====================
However/RB
,/,
as/IN
mentioned/VBN
previously/RB
,/,
it/PRP
is/VBZ
technically/RB
challenging/VBG
to/TO
detect/VB
and/CC
evaluate/VBP
rare/JJ
heterozygous/JJ
variants/NNS
because/IN
heterozygous/JJ
variant/JJ
calling/JJ
is/VBZ
more/RBR
susceptible/JJ
to/TO
the/DT
technical/JJ
errors/NNS
and/CC
require/VB
higher/JJR
read/RB
depth/NN
./.
====================
For/IN
example/NN
,/,
at/IN
a/DT
coverage/JJ
depth/NN
of/IN
4×/CD
(/(
i.e./FW
,/,
if/IN
a/DT
base/NN
is/VBZ
covered/VBN
by/IN
4/CD
independent/JJ
reads/VBZ
)/)
and/CC
assuming/VBG
a/DT
1/CD
%/NN
per-base/NN
error/JJ
rate/NN
,/,
a/DT
homozygous/JJ
variant/JJ
will/MD
be/VB
called/VBN
if/IN
0/CD
and/CC
4/CD
reads/VBZ
are/VBP
observed/VBN
for/IN
the/DT
reference/NN
and/CC
nonreference/RB
alleles/NNS
respectively/RB
,/,
with/IN
a/DT
false/JJ
positive/JJ
rate/NN
of/IN
2/CD
×/NNP
10-4/CD
./.
====================
However/RB
,/,
if/IN
both/CC
reference/VBP
and/CC
nonreference/NN
alleles/NNS
have/VBP
2×/CD
coverage/NN
,/,
a/DT
heterozygous/JJ
variant/JJ
will/MD
be/VB
called/VBN
with/IN
a/DT
false/JJ
positive/JJ
rate/NN
of/IN
0.34/CD
./.
====================
This/DT
presents/VBZ
a/DT
particular/JJ
problem/NN
when/WRB
one/CD
considers/VBZ
the/DT
uneven/JJ
coverage/NN
in/IN
WES/NN
resulting/VBG
from/IN
differential/JJ
capture/NN
efficiencies/NNS
across/IN
the/DT
exome/JJ
./.
====================
To/TO
achieve/VB
reliable/JJ
heterozygous/JJ
calling/JJ
,/,
it/PRP
is/VBZ
therefore/RB
necessary/JJ
to/TO
achieve/VB
sufficient/JJ
coverage/NN
depth/NN
across/IN
the/DT
entire/JJ
exome/JJ
so/RB
as/IN
to/TO
minimize/VB
the/DT
number/NN
of/IN
bases/NNS
with/IN
low/JJ
coverage/NN
./.
====================
Another/DT
challenge/NN
to/TO
analysis/NN
is/VBZ
read/VBN
misalignments/NNS
;/:
the/DT
typical/JJ
length/NN
of/IN
NGS/NN
reads/VBZ
is/VBZ
near/JJ
or/CC
less/RBR
than/IN
100/CD
bp/NN
,/,
and/CC
even/RB
paired/JJ
reads/VBZ
are/VBP
subject/JJ
to/TO
being/VBG
improperly/RB
aligned/RB
,/,
because/IN
there/EX
are/VBP
large/JJ
portions/NNS
of/IN
the/DT
human/JJ
genome/NN
where/WRB
the/DT
DNA/NN
sequence/NN
is/VBZ
highly/RB
repetitive/JJ
and/CC
duplicated/JJ
./.
====================
In/IN
fact/NN
,/,
segmental/JJ
duplicated/JJ
regions/NNS
,/,
defined/VBN
as/IN
intervals/NNS
larger/JJR
than/IN
1/CD
kb/NN
having/VBG
a/DT
homology/NN
>/JJR
90/CD
%/NN
with/IN
other/JJ
parts/NNS
of/IN
the/DT
genome/NN
,/,
encompass/VBP
about/RB
5/CD
%/NN
of/IN
the/DT
human/JJ
genome/NN
[/(
15/CD
]/)
./.
====================
Hence/RB
,/,
imposing/VBG
more/RBR
rigorous/JJ
filtering/VBG
criteria/NNS
to/TO
remove/VB
such/JJ
reads/VBZ
,/,
including/VBG
Phred/JJ
score/RB
and/CC
mapping/NN
quality/NN
score/RB
cutoffs/NNS
,/,
is/VBZ
essential/JJ
./.
====================
The/DT
recent/JJ
,/,
dramatic/JJ
acceleration/NN
in/IN
human/JJ
population/NN
growth/NN
over/IN
the/DT
last/JJ
several/JJ
millennia/NN
has/VBZ
resulted/VBD
in/IN
an/DT
excess/NN
of/IN
rare/JJ
variants/NNS
in/IN
the/DT
human/JJ
genome/NN
,/,
and/CC
these/DT
variants/NNS
have/VBP
not/RB
had/VBD
enough/IN
time/NN
to/TO
be/VB
subjected/VBN
to/TO
natural/JJ
selection/NN
[/(
14/CD
]/)
./.
====================
Since/IN
the/DT
identification/NN
of/IN
disease-associated/JJ
variants/NNS
consists/VBZ
largely/RB
of/IN
assessing/VBG
rare/JJ
variants/NNS
,/,
one/CD
must/MD
bear/VB
in/IN
mind/JJ
the/DT
possibility/NN
that/IN
a/DT
variant/JJ
of/IN
interest/NN
could/MD
be/VB
population-specific/JJ
and/CC
not/RB
necessarily/RB
disease-causing/VBG
./.
====================
This/DT
is/VBZ
especially/RB
problematic/JJ
if/IN
the/DT
patient/NN
cohort/VBP
is/VBZ
not/RB
of/IN
European/JJ
or/CC
,/,
more/RBR
specifically/RB
,/,
northwestern/NN
European/NN
descent/JJ
./.
====================
Recent/JJ
public/JJ
sequencing/NN
projects/NNS
,/,
such/JJ
as/IN
the/DT
1000/CD
Genomes/NNS
Project/JJ
and/CC
NHLBI/NN
Go/NN
Exome/NN
Sequencing/NN
Project/JJ
,/,
have/VBP
covered/VBN
a/DT
greater/JJR
variety/NN
of/IN
non-European/JJ
ethnic/JJ
groups/NNS
than/IN
before/IN
,/,
and/CC
they/PRP
report/VBP
that/IN
these/DT
groups/NNS
harbor/VBP
a/DT
greater/JJR
burden/NN
of/IN
rare/JJ
variants/NNS
as/IN
compared/VBN
to/TO
Europeans/NNS
[/(
14/CD
,/,
16/CD
]/)
./.
====================
For/IN
example/NN
,/,
indigenous/JJ
African/JJ
individuals/NNS
may/MD
carry/VB
2-3/CD
times/NNS
more/RBR
rare/JJ
variants/NNS
,/,
and/CC
East/JJ
Asian/JJ
individuals/NNS
may/MD
carry/VB
1.5/CD
times/NNS
more/RBR
variants/NNS
when/WRB
compared/VBN
to/TO
individuals/NNS
of/IN
European/JJ
descent/JJ
./.
====================
Rare/RB
variants/NNS
specific/JJ
to/TO
the/DT
population/NN
of/IN
study/NN
might/MD
be/VB
easily/RB
mistaken/NN
as/IN
patient-enriched/VBN
variants/NNS
;/:
it/PRP
is/VBZ
thus/RB
necessary/JJ
to/TO
screen/VB
the/DT
presumed/VBN
variant/JJ
with/IN
carefully/RB
matched/VBN
healthy/JJ
individuals/NNS
./.
====================
Locus/FW
heterogeneity/NN
describes/VBZ
the/DT
phenomenon/NN
where/WRB
a/DT
single/JJ
disease/NN
can/MD
be/VB
caused/VBN
by/IN
multiple/JJ
different/JJ
loci/NNS
across/IN
different/JJ
patients/NNS
./.
====================
Over/RB
the/DT
last/JJ
few/JJ
decades/NNS
,/,
studies/NNS
performing/VBG
linkage/NN
analysis/NN
followed/VBD
by/IN
positional/JJ
cloning/VBG
have/VBP
identified/VBN
many/JJ
genes/NNS
as/IN
being/VBG
responsible/JJ
for/IN
various/JJ
inherited/VBN
diseases/NNS
;/:
the/DT
Online/NN
Mendelian/JJ
Inheritance/NN
in/IN
Man/JJ
(/(
OMIM/NN
)/)
database/NN
currently/RB
records/VBZ
3,000/CD
genes/NNS
as/IN
being/VBG
disease-causing/VBG
(/(
http/NN
:/:
//www.ncbi.nlm.nih.gov/omim/JJ
)/)
./.
====================
This/DT
also/RB
suggests/VBZ
that/IN
the/DT
majority/NN
of/IN
the/DT
remaining/VBG
diseases/NNS
without/IN
known/VBN
associations/NNS
with/IN
genes/NNS
have/VBP
not/RB
been/VBN
amenable/JJ
to/TO
classical/JJ
approaches/NNS
and/CC
will/MD
likely/RB
display/VBP
extensive/JJ
genetic/JJ
heterogeneity/NN
./.
====================
Increasing/VBG
the/DT
size/NN
of/IN
the/DT
patient/NN
cohort/VBP
will/MD
increase/VB
the/DT
power/NN
to/TO
discover/JJ
variants/NNS
,/,
as/IN
shown/VBN
in/IN
Fig/NN
./.
====================
3/CD
./.
====================
Pathway/NN
or/CC
gene/NN
ontology/NN
analyses/NNS
can/MD
also/RB
be/VB
performed/VBN
to/TO
link/VB
the/DT
mutated/VBN
genes/NNS
into/IN
certain/JJ
functional/JJ
categories-there/NN
are/VBP
several/JJ
publicly/RB
available/JJ
tools/NNS
for/IN
this/DT
purpose/NN
./.
====================
A/DT
good/JJ
example/NN
of/IN
this/DT
method/NN
is/VBZ
the/DT
aforementioned/VBN
study/NN
on/IN
PHAII-the/DT
authors/NNS
initially/RB
identified/VBN
KLHL3/NN
from/IN
WES/NN
of/IN
11/CD
patients/NNS
and/CC
subsequently/RB
considered/VBN
KLHL3/NN
's/POS
presumed/VBN
functional/JJ
partner/NN
,/,
CUL3/NN
,/,
as/IN
a/DT
potential/JJ
gene/NN
candidate/NN
./.
====================
Extending/VBG
the/DT
screening/NN
to/TO
52/CD
patients/NNS
,/,
KLHL3/NN
was/VBD
found/VBN
to/TO
be/VB
mutated/VBN
in/IN
24/CD
patients/NNS
(/(
46.2/CD
%/NN
)/)
and/CC
CUL3/NN
in/IN
another/DT
17/CD
patients/NNS
(/(
32.7/CD
%/NN
)/)
,/,
explaining/VBG
a/DT
total/JJ
of/IN
78.8/CD
%/NN
of/IN
the/DT
entire/JJ
patient/NN
set/NN
./.
====================
Another/DT
possible/JJ
approach/NN
is/VBZ
to/TO
re-evaluate/VB
the/DT
clinical/JJ
diagnosis/NN
of/IN
patients/NNS
in/IN
the/DT
cohort/JJ
by/IN
correlating/VBG
subtle/JJ
differences/NNS
of/IN
clinical/JJ
measurements/NNS
and/CC
genetic/JJ
variants/NNS
in/IN
order/NN
to/TO
focus/VB
the/DT
analysis/NN
on/IN
a/DT
more/RBR
clinically/RB
homogeneous/JJ
set/NN
of/IN
patients/NNS
as/IN
a/DT
separate/JJ
cohort/JJ
./.
====================
There/EX
is/VBZ
no/DT
doubt/JJ
that/DT
NGS/NN
has/VBZ
provided/VBN
researchers/NNS
with/IN
unprecedented/JJ
power/JJR
to/TO
resolve/VB
the/DT
genetic/JJ
etiology/NN
of/IN
various/JJ
human/JJ
diseases/NNS
./.
====================
When/WRB
WES/NN
was/VBD
first/JJ
introduced/JJ
,/,
its/PRP$
utility/NN
was/VBD
highly/RB
debated/VBN
due/JJ
to/TO
its/PRP$
apparent/JJ
limitations/NNS
,/,
such/JJ
as/IN
incomplete/JJ
coverage/NN
of/IN
functional/JJ
elements/NNS
and/CC
low/JJ
sensitivity/NN
for/IN
structural/JJ
variant/JJ
detection/NN
./.
====================
However/RB
,/,
the/DT
practical/JJ
advantages/VBZ
of/IN
the/DT
technology/NN
have/VBP
made/VBN
it/PRP
a/DT
favored/JJ
tool/NN
for/IN
researchers/NNS
,/,
and/CC
WES/NN
will/MD
likely/RB
continue/NN
to/TO
be/VB
widely/RB
used/VBN
for/IN
the/DT
foreseeable/JJ
future/JJ
./.
====================
Furthermore/RB
,/,
as/IN
library/NN
capture/NN
methods/NNS
and/CC
data/NNS
analysis/NN
pipelines/NNS
improve/VBP
,/,
increasing/VBG
amounts/NNS
of/IN
genomic/JJ
information/NN
,/,
aside/NN
from/IN
single-nucleotide/JJ
changes/NNS
and/CC
short/JJ
indels/VBZ
,/,
can/MD
be/VB
extracted/VBN
./.
====================
Examples/NNS
of/IN
this/DT
include/VBP
homozygosity/NN
interval/JJ
mapping/VBG
,/,
common/JJ
SNP/NN
genotyping/VBG
information/NN
for/IN
various/JJ
population-level/JJ
analyses/NNS
,/,
and/CC
detection/NN
of/IN
structural/JJ
variants/NNS
[/(
17/CD
,/,
18/CD
]/)
./.
====================
Finally/RB
,/,
the/DT
strengths/NNS
of/IN
WES-short/NN
turnaround/NN
times/NNS
,/,
low/JJ
cost/JJ
,/,
and/CC
relatively/RB
easy/JJ
data/NNS
interpretation-make/VBP
it/PRP
an/DT
optimal/JJ
tool/NN
for/IN
clinical/JJ
diagnosis/NN
./.
====================
The/DT
increased/VBN
use/NN
of/IN
WES/NN
in/IN
the/DT
clinic/JJ
will/MD
surely/RB
spur/NN
the/DT
development/NN
of/IN
personalized/VBN
medicine/NN
and/CC
reinvent/JJ
treatment/NN
practices/VBZ
in/IN
the/DT
near/JJ
future/JJ
[/(
1/CD
,/,
19/CD
]/)
./.
====================
Increasing/VBG
number/NN
of/IN
whole/JJ
exome/NN
sequencing/NN
papers/NNS
over/IN
time/NN
./.
====================
Overview/NN
of/IN
whole/JJ
exome/NN
sequencing/NN
pipeline/NN
./.
====================
SNV/NN
,/,
single/JJ
nucleotide/NN
variant/JJ
./.
====================
Increased/VBN
sensitivity/NN
to/TO
detect/VB
causal/JJ
gene/NN
as/IN
patient/NN
cohort/VBP
size/NN
increases/VBZ
./.
====================
Percentages/NNS
shown/VBN
denote/IN
ratio/NN
of/IN
patients/NNS
that/WDT
carry/VBP
rare/JJ
functional/JJ
variants/NNS
./.
====================
Simulation/NN
was/VBD
performed/VBN
assuming/VBG
that/DT
0.1/CD
%/NN
of/IN
healthy/JJ
controls/NNS
carry/VBP
rare/JJ
functional/JJ
variants/NNS
,/,
and/CC
was/VBD
iterated/VBN
105/CD
times/NNS
./.
====================
Each/DT
iteration/NN
was/VBD
evaluated/VBN
and/CC
called/VBN
'detected/JJ
'/``
if/IN
the/DT
p-value/NN
exceeded/VBN
the/DT
genome-wide/NN
significance/NN
./.
====================
